Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2011

View Archived Issues

Phase III data on rivaroxaban in subjects with acute coronary syndromes

Human monoclonal antibodies show anticancer potential in preclinical and clinical settings

TMED10 gene SNP linked to Alzheimer's disease

Patrys raises funds to support anticancer pipeline

Medicis completes acquisition

U3-1287 combinations assessed in lung and pharynx cancer

Kowa identifies new cholesterol ester transfer protein inhibitors

New triterpenoid derivatives prepared by Concert Pharmaceuticals

Purdue exercises option to commercialize Intermezzo

Novel GPR119 receptor agonists disclosed by Bristol-Myers Squibb

Infinity Pharmaceuticals patents novel fatty acid synthase inhibitors

Zalicus begins phase I study of new Z-160 formulation

Spectrum Pharmaceuticals files IND with FDA for phosphate-binding agent

Scientists at Merck & Co. synthesize new fatty-acid amide hydrolase inhibitors

Belgian university discloses novel Amaryllidaceae isocarbostyryl derivatives for cancer

New 11-beta-HSD1 inhibitors patented in Korea

Targacept launches two new clinical studies of TC-5619

Pfizer finalizes acquisition

AtheroNova and Maxwell Biotech ratify agreement for AHRO-001

Oncolytics Biotech reports on Reolysin in pancreatic cancer

Achillion discloses preliminary proof-of-concept data on ACH-2928 and advances ACH-3102

Pivotal trial of cobicistat meets primary endpoint

ViroPharma and Halozyme report topline data from hereditary angioedema study

Second milestone reached in GenVec/Novartis collaboration

FDA accepts Cell Therapeutics' resubmission of pixantrone NDA as complete

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...